RBC Capital Maintains Outperform on Aptose Biosciences, Lowers Price Target to $40
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza maintains an Outperform rating on Aptose Biosciences (NASDAQ:APTO) but lowers the price target from $75 to $40.
June 07, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains Outperform rating on Aptose Biosciences but lowers price target from $75 to $40.
The news directly mentions Aptose Biosciences (APTO) and the lowered price target by RBC Capital. While the Outperform rating is maintained, the reduced price target may cause mixed reactions among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100